Sands Capital Life Sciences Pulse Fund II, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT)

Filing manager
Sands Capital Life Sciences Pulse Fund II, L.P.
Reporting owner
Sands Capital Life Sciences Pulse Fund II, L.P.
Security
Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share
Beneficially owned shares
13,018,965 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

11%

Beneficial ownership of this reported class.

Shares

13,018,965 shares

Shares beneficially owned as disclosed.

Event date

31 Dec 2025

Date tied to the ownership event or amendment.

Accepted by SEC

13 Feb 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
11%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
IKT
Shares outstanding
120,545,972 shares
Source evidence Original filing metadata and source links for verification. 6 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
13 Feb 2026, 11:30:46 UTC
Event date
31 Dec 2025
Prior SEC filing
13 Aug 2025
Next SEC filing
13 Aug 2026
Source filing
View source filing

Key filing fact

Sands Capital Life Sciences Pulse Fund II, L.P. disclosed 11% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT) on 31 Dec 2025.

Key facts

  • Sands Capital Life Sciences Pulse Fund II, L.P. filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT).
  • Disclosed ownership: 11%.
  • Date of event: 31 Dec 2025.

Change

  • Previous schedule filing date: 13 Aug 2025.
  • Current filing was accepted on 13 Feb 2026, 11:30.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (3)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Sands Capital Life Sciences Pulse Fund II, L.P. 11% 13,018,965 13,018,965 /s/ Jonathan Goodman Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Sands Capital Alternatives, LLC 11% 13,018,965 13,018,965 /s/ Jonathan Goodman Jonathan Goodman, General Counsel
SANDS FRANK M. 11% 13,018,965 13,018,965 /s/ Frank M. Sands Frank M. Sands
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .